No black box warning on record for Alhemo

As of the latest FDA labeling reviewed, Alhemo (CONCIZUMAB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Alhemo medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Thromboembolic Events: Monitor patients for thromboembolic events. Advise patients to report signs and symptoms, and if they occur discontinue prophylaxis. ( 5.1 ) • Hypersensitivity Reactions: In the event of a severe hypersensitivity reaction, discontinue Alhemo. ( 5.2 ) • Increased Laboratory Values of Fibrin D dimer and Prothrombin Fragment 1.2: Alhemo increases va

No black box warning on record for Alhemo

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Thromboembolic Events: Monitor patients for thromboembolic events. Advise patients to report signs and symptoms, and if they occur discontinue prophylaxis. ( 5.1 ) • Hypersensitivity Reactions: In the event of a severe hypersensitivity reaction, discontinue Alhemo. ( 5.2 ) • Increased Laboratory Values of Fibrin D dimer and Prothrombin Fragment 1.2: Alhemo increases va

Alhemo Black Box Warning

No black box warning on record for Alhemo

Other warnings & precautions

Alhemo Black Box Warning

No black box warning on record for Alhemo

Other warnings & precautions